1.1. Program Leaders. Co-Leader (Clinical Research) - Claudine Isaacs, MD. Dr. Claudine Isaacs Is an Associate Professor in the Departments of Medicine and Oncology; she assumed the position of the Breast Cancer Program Clinical Co-Leader in 2001. Dr. Isaacs received her medical degree (MDCM) and residency training at McGill University (Canada). Following fellowship training in the Division of Medical Oncology at Georgetown University, she joined the faculty in the Department of Medicine (Division of Hematology and Medical Oncology) and she is now also a member in the Department of Oncology. Her research interests include genetic testing, breast cancer treatment, and prevention strategies for women at high risk of breast cancer. In addition, she has served as the PI of a variety of clinical trials In breast cancer screening and prevention, early-stage disease, and metastatic disease. Dr. Isaacs has been a longstanding member of the BC Program and serves as Co-Director of the Jess and Mildred Fisher Center for Familial Cancer Research of the Lombardi Comprehensive Cancer Center. She recently co-chaired a multi-institutional study of breast screening in genetically high-risk women and is currently conducting a Phase 2 trial of sorafenib and anastrazole in metastatic breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA051008-19
Application #
8375510
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
19
Fiscal Year
2012
Total Cost
$42,006
Indirect Cost
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Czarnecka, Magdalena; Lu, Congyi; Pons, Jennifer et al. (2018) Neuropeptide Y receptor interactions regulate its mitogenic activity. Neuropeptides :
Gonzalez, Thomas L; Moos, Rebecca K; Gersch, Christina L et al. (2018) Metabolites of n-Butylparaben and iso-Butylparaben Exhibit Estrogenic Properties in MCF-7 and T47D Human Breast Cancer Cell Lines. Toxicol Sci 164:50-59
Singh, Zeba N; Duong, Vu H; Koka, Rima et al. (2018) High-Risk Acute Promyelocytic Leukemia with Unusual T/Myeloid Immunophenotype Successfully Treated with ATRA and Arsenic Trioxide-Based Regimen. J Hematop 11:67-74
Pannkuk, Evan L; Laiakis, Evagelia C; Fornace Jr, Albert J et al. (2018) A Metabolomic Serum Signature from Nonhuman Primates Treated with a Radiation Countermeasure, Gamma-tocotrienol, and Exposed to Ionizing Radiation. Health Phys 115:3-11
da Cruz, Raquel Santana; Carney, Elissa J; Clarke, Johan et al. (2018) Paternal malnutrition programs breast cancer risk and tumor metabolism in offspring. Breast Cancer Res 20:99
Fan, Ping; Tyagi, Amit K; Agboke, Fadeke A et al. (2018) Modulation of nuclear factor-kappa B activation by the endoplasmic reticulum stress sensor PERK to mediate estrogen-induced apoptosis in breast cancer cells. Cell Death Discov 4:15
Dash, Chiranjeev; Taylor, Teletia R; Makambi, Kepher H et al. (2018) Effect of exercise on metabolic syndrome in black women by family history and predicted risk of breast cancer: The FIERCE Study. Cancer 124:3355-3363
Lynce, Filipa; Blackburn, Matthew J; Cai, Ling et al. (2018) Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials. Breast Cancer Res Treat 168:35-41
Paffhausen, Emily S; Alowais, Yasir; Chao, Cara W et al. (2018) Discovery of a stem-like multipotent cell fate. Am J Stem Cells 7:25-37
Lee, Shiao-Pieng; Kao, Chen-Yu; Chang, Shun-Cheng et al. (2018) Tissue distribution and subcellular localizations determine in vivo functional relationship among prostasin, matriptase, HAI-1, and HAI-2 in human skin. PLoS One 13:e0192632

Showing the most recent 10 out of 1120 publications